| Name | Title | Contact Details |
|---|
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.
At ImmunoFlex™ we share an interest in understanding the human immune system and how different compounds have the potential to strengthen, support, and enhance our body`s natural surveillance and response system.
As a nonprofit engineering innovation company, Draper serves our nation`s interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers` needs and to deliver new capabilities to them.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.